Serum Troponin T Concentrations Are Frequently Elevated in Advanced Skin Cancer Patients Prior to Immune Checkpoint Inhibitor Therapy: Experience From a Single Tertiary Referral Center.
immune checkpoint inhibition
melanoma
myocarditis
non-melanoma skin cancer
troponin
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
04
2021
accepted:
20
04
2021
entrez:
22
7
2021
pubmed:
23
7
2021
medline:
23
7
2021
Statut:
epublish
Résumé
Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of several human malignancies, particularly metastatic skin cancer. However, immune-related myocarditis (irM), an immune-mediated adverse event (irAE), is often fatal. In the absence of a reliable biomarker, measurement of pre-ICI therapy serum troponin concentration has been proposed to identify patients at risk of developing irM, although real-world studies examining this strategy are lacking. Thus, we retrospectively analyzed the case records of all patients who commenced ICI therapy between January 2018 and December 2019 in a single university skin cancer center (
Identifiants
pubmed: 34291066
doi: 10.3389/fmed.2021.691618
pmc: PMC8288046
doi:
Types de publication
Journal Article
Langues
eng
Pagination
691618Informations de copyright
Copyright © 2021 Kurzhals, Graf, Boch, Grzyska, Frydrychowicz, Zillikens, Terheyden and Langan.
Déclaration de conflit d'intérêts
EL reports personal fees and non-financial support from Bristol Myers Squibb, personal fees and non-financial support from Novartis, Meeting and travel support from Curevac, and advisory board fees from Sun Pharma. PT speaker's honoraria from BMS, Novartis, MSD, Pierre-Fabre, CureVac, and Roche, consultant's honoraria from BMS, Novartis, Pierre-Fabre, Merck Serono, Sanofi, and Roche and travel support from BMS, Pierre-Fabre, and Roche. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JAMA Dermatol. 2016 Jan;152(1):45-51
pubmed: 26501224
Curr Cardiol Rep. 2017 Mar;19(3):21
pubmed: 28220466
Lancet Oncol. 2018 Sep;19(9):e447-e458
pubmed: 30191849
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Am J Cardiol. 2020 Jun 15;125(12):1920-1926
pubmed: 32312493
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Diabetes. 2020 Apr;69(4):713-723
pubmed: 31974140
Front Pharmacol. 2020 Jun 26;11:972
pubmed: 32676031
J Cancer Res Clin Oncol. 2021 Jun;147(6):1623-1630
pubmed: 33837821
Science. 2001 Jan 12;291(5502):319-22
pubmed: 11209085
Diabetes Care. 2017 Feb;40(2):261-269
pubmed: 28108537
Clin Biochem. 2013 Aug;46(12):1135-1138
pubmed: 23660299
Emerg Radiol. 2020 Aug;27(4):455-460
pubmed: 32130542
Lancet. 2018 Mar 10;391(10124):933
pubmed: 29536852
J Am Coll Cardiol. 2018 Apr 24;71(16):1755-1764
pubmed: 29567210
Int J Cardiovasc Imaging. 2018 Jan;34(1):35-54
pubmed: 28130644
Circulation. 2007 Oct 30;116(18):2062-71
pubmed: 17938288
Radiology. 2014 Nov;273(2):383-92
pubmed: 24910904
Diabetes Res Clin Pract. 2012 Jul;97(1):139-45
pubmed: 22579531
Curr Oncol. 2019 Jun;26(3):e418-e421
pubmed: 31285688
Oncologist. 2018 Aug;23(8):874-878
pubmed: 29802220
Immunotherapy. 2021 Feb;13(3):257-270
pubmed: 33225800
Am J Cancer Res. 2016 Oct 01;6(10):2117-2128
pubmed: 27822406
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
ESMO Open. 2017 Oct 26;2(4):e000247
pubmed: 29104763
Curr Probl Cancer. 2017 Mar - Apr;41(2):125-128
pubmed: 28190531
Oncologist. 2018 Aug;23(8):879-886
pubmed: 29802219
N Engl J Med. 2016 Nov 03;375(18):1749-1755
pubmed: 27806233
Eur J Cancer. 2016 Feb;54:139-148
pubmed: 26765102
Heart. 2015 Dec;101(23):1874-80
pubmed: 26416836
Nat Med. 2003 Dec;9(12):1477-83
pubmed: 14595408
J Cardiothorac Surg. 2006 Oct 23;1:37
pubmed: 17059599
Nutr Metab (Lond). 2017 Nov 25;14:73
pubmed: 29204182
Chronic Dis Transl Med. 2019 Mar 21;5(1):6-14
pubmed: 30993259
Curr Oncol Rep. 2018 Apr 11;20(6):44
pubmed: 29644505
JAMA Oncol. 2018 Dec 1;4(12):1721-1728
pubmed: 30242316
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
JAMA Netw Open. 2019 May 3;2(5):e192535
pubmed: 31050774
Circulation. 2017 Nov 21;136(21):2085-2087
pubmed: 29158217
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
Melanoma Res. 2017 Apr;27(2):155-158
pubmed: 27977496
Asia Pac J Clin Oncol. 2020 Aug;16(4):232-240
pubmed: 32129935
Sci Rep. 2017 Feb 01;7:41350
pubmed: 28145489
Circ Res. 2007 Aug 3;101(3):248-57
pubmed: 17569889
Clin Res Cardiol. 2020 Oct;109(10):1197-1222
pubmed: 32405737
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
Cardiol Rev. 2019 Mar/Apr;27(2):97-107
pubmed: 29912044